by A recent study by researchers at the University of California San Diego School of Medicine has shed new light on the potential benefits of thiazolidinediones (TZDs), a class of drugs that were once widely used for treating type 2 diabetes. Despite their decline in popularity due to undesirable side effects, such as weight gain and fluid retention, scientists believe that isolating the positive effects of these drugs could lead to the development of safer and more effective treatments for insulin resistance, a key aspect of type 2 diabetes.
TZD drugs have long been known for their ability to reverse insulin resistance, a condition at the core of type 2 diabetes. However, their use has waned over the years due to the associated side effects. The researchers at UC San Diego sought to uncover how one of the well-known TZD drugs functions at a molecular level. Through their study published in Nature Metabolism, they were able to replicate the beneficial effects of the drug in mice without administering the drug itself.
Lead researcher Jerrold Olefsky, M.D., highlighted the significance of developing treatments that can safely address insulin resistance, given its pivotal role in type 2 diabetes. With obesity driving insulin resistance in a significant portion of the population, there is a growing need for innovative therapies that can effectively tackle this condition.
One of the key findings of the study was the role of inflammation in exacerbating insulin resistance. In obese individuals, inflammation triggers the release of microRNAs within exosomes by immune cells in adipose tissue. These exosomes containing genetic instructions can travel to other tissues in the body, contributing to metabolic changes like insulin resistance.
By treating obese mice with a TZD drug, the researchers observed improved insulin sensitivity alongside weight gain and fluid retention. However, by isolating exosomes from these mice and transferring them to another group of obese mice, they were able to deliver the positive effects of the drug without the adverse reactions. This manipulation of exosomes demonstrated the potential for developing new therapies that mimic the effects of TZD drugs without causing unwanted side effects.
Moreover, the researchers identified a specific microRNA, miR-690, within the exosomes that was responsible for the beneficial metabolic effects observed. Harnessing the potential of this molecule could pave the way for novel treatments for type 2 diabetes that target insulin resistance.
While directly using exosomes as a therapeutic approach may pose challenges in terms of production and administration, understanding the underlying mechanisms of these beneficial effects opens up possibilities for developing drugs that can replicate these effects. The researchers are particularly interested in exploring the potential of using microRNAs as drugs, with miR-690 showing promise for future investigations.
The study represents a significant milestone in unraveling the therapeutic potential of TZD drugs in a more targeted and efficient manner. By leveraging the insights gained from this research, scientists aim to pave the way for novel treatments that can effectively address insulin resistance in patients with type 2 diabetes.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
